Top Tweets for #tzield
#Tzield demuestra beneficios en niños con diagnóstico de #diabetestipo1
Una nueva aprobación de la FDA representa un avance importante para niños y adolescentes que viven con diabetes tipo 1. https://t.co/QNSfU8TH5l
The #FDA has approved a #teplizumab (#Tzield) for pediatric patients with Stage 3 #T1D: A major step forward in pediatric type 1 diabetes care.
#FDAApproval #Type1Diabetes #Endocrinology #DiabetesResearch #PharmaNews #DrugDiscovery #MedicinalChemistry
💊#FDAApproval Update | The FDA has approved a #teplizumab (#Tzield) for pediatric patients with Stage 3 #T1D
💡Delays the onset of Stage 3 T1D
💡Slows down the loss of insulin production
🩸Type 1 diabetes is a progressive autoimmune condition, and Stage 3 represents the point where clinical symptoms appear and insulin therapy becomes necessary
This approval:
📈Supports earlier intervention in disease progression
💊Expands treatment options for pediatric patients at diagnosis
#FDAApproval #Type1Diabetes #Endocrinology #DiabetesResearch #PharmaNews #DrugDiscovery #MedicinalChemistry
💊#FDAApproval Update | The FDA has approved a #teplizumab (#Tzield) for pediatric patients with Stage 3 #T1D
💡Delays the onset of Stage 3 T1D
💡Slows down the loss of insulin production
🩸Type 1 diabetes is a progressive autoimmune condition, and Stage 3 represents the point where clinical symptoms appear and insulin therapy becomes necessary
This approval:
📈Supports earlier intervention in disease progression
💊Expands treatment options for pediatric patients at diagnosis
#FDAApproval #Type1Diabetes #Endocrinology #DiabetesResearch #PharmaNews #DrugDiscovery #MedicinalChemistry
.@US_FDA slowdown on #Tzield sBLA underlines #CNPV questions https://t.co/IRKVKDt3o8 #biopharma #type1diabetes @Sanofi
#Tzield es la primera terapia para #niños de un año en adelante diagnosticados con #DT1 en etapa 2
Un importante avance en el manejo de la #diabetestipo1 abre nuevas oportunidades para pacientes pediátricos y sus familias https://t.co/c5VFVYzmBJ
@zethedeuce Also mechanistic overlap with $SNY anti-CD3 #Tzield, based on $CRVS oral #soquelitinib MOA it should be more than plausible as a treatment in T1D, see below
https://t.co/er2z0C5DV0
Comparison of $SNY #Tzield and $CRVS #soquelitinib MOA effects/potential T1D:
🔹Tzield (teplizumab), a CD3 monoclonal antibody delays Type 1 Diabetes (T1D) onset by reducing T-cell receptor TCR signal strength and boosting regulatory T-cells (Tregs), as shown in a 2022 NEJM study demonstrating preserved β-cell function in patients
🔹#ITK inhibition by Corvus soquelitinib modulates TCR signal and #mTOR activity to favor #Th1 and #Treg production while suppressing pathogenic #Th2 + #Th17 cells. Overlap MOA may offer safer oral alternative to Tzield’s intravenous delivery, w/ Corvus’ approach avoiding the immunosuppression risks of earlier non-selective kinase inhibitors like #ibrutinib.
New Board addition from $NVO, this potential for ITK inhibition in a metabolic disease like T1D may be of interest.
@tradingsssss @zethedeuce I have written about overlap in MOA for $SNY #Tzield and $CRVS #ITK inhibitor approach w/ #soquelitinib⤵️ and seperately Corvus already shown Ph1b N=48 patients across all cohorts SQL is getting better EASI-75 reduction than Dupi in same time frame!
https://t.co/er2z0C5DV0
Comparison of $SNY #Tzield and $CRVS #soquelitinib MOA effects/potential T1D:
🔹Tzield (teplizumab), a CD3 monoclonal antibody delays Type 1 Diabetes (T1D) onset by reducing T-cell receptor TCR signal strength and boosting regulatory T-cells (Tregs), as shown in a 2022 NEJM study demonstrating preserved β-cell function in patients
🔹#ITK inhibition by Corvus soquelitinib modulates TCR signal and #mTOR activity to favor #Th1 and #Treg production while suppressing pathogenic #Th2 + #Th17 cells. Overlap MOA may offer safer oral alternative to Tzield’s intravenous delivery, w/ Corvus’ approach avoiding the immunosuppression risks of earlier non-selective kinase inhibitors like #ibrutinib.
New Board addition from $NVO, this potential for ITK inhibition in a metabolic disease like T1D may be of interest.
🔥 A new chapter for #T1D #immunotherapy
@Sanofi’s #Tzield (#teplizumab) receives expedited @FDA review 🧬
🎯 Goal: preserve β-cell function in recent-onset (stage 3) T1D
💡 Backed by PROTECT phase 3
⏳ Decision expected within weeks
🔗 https://t.co/4i2IRbbSff
#EndoTwitter
Comparison of $SNY #Tzield and $CRVS #soquelitinib MOA effects/potential T1D:
🔹Tzield (teplizumab), a CD3 monoclonal antibody delays Type 1 Diabetes (T1D) onset by reducing T-cell receptor TCR signal strength and boosting regulatory T-cells (Tregs), as shown in a 2022 NEJM study demonstrating preserved β-cell function in patients
🔹#ITK inhibition by Corvus soquelitinib modulates TCR signal and #mTOR activity to favor #Th1 and #Treg production while suppressing pathogenic #Th2 + #Th17 cells. Overlap MOA may offer safer oral alternative to Tzield’s intravenous delivery, w/ Corvus’ approach avoiding the immunosuppression risks of earlier non-selective kinase inhibitors like #ibrutinib.
New Board addition from $NVO, this potential for ITK inhibition in a metabolic disease like T1D may be of interest.
Teplizumab: a new hope for people affected by #diabetes.
"A new drug slows insulin-dependent diabetic deterioration and has sped up development of a complete remedy."
#Science #Health #Medicine #Diabetesresearch
⏯️A Cure for Type 1 Diabetes Seems Close, Thanks to New Drugs and Tech
https://t.co/t5V5mY5oXS
Comparison of $SNY #Tzield and $CRVS #soquelitinib MOA effects:
🔹Tzield (teplizumab), a CD3 monoclonal antibody that delays Type 1 Diabetes (T1D) onset by reducing T-cell receptor signal strength and boosting regulatory T-cells (Tregs), as shown in a 2022 NEJM study demonstrating preserved β-cell function in newly diagnosed patients.
🔹Tzield’s mechanism mirrors the selective #ITK inhibition by Corvus Pharmaceuticals’ soquelitinib, which modulates #mTOR activity to favor #Th1 and #Treg production while suppressing pathogenic #Th2/#Th17 cells, suggesting a safer oral alternative to Tzield’s intravenous delivery, with Corvus’ approach avoiding the immunosuppression risks of earlier non-selective kinase inhibitors like #ibrutinib.
Biotech Buyout Flashback:
🔹2023 $SNY buys Provention Bio for $2.9B: $25/sh a 273% premium over $6.70
🔹Drug: #CD3 mAb #Tzield #teplizumab
🔹MOA reduces T-cell TCR signal strength and #mTOR activity in CD8+ Tcells and Increases #Tregs
🔹Target Indication: Type 1 Diabetes #T1D
https://t.co/8VaLIVjHMB
anti-CD3 similar downstream effects to ITK inhibition, but $CRVS ITKi #soquelitinib oral safer
Corvus $CRVS highly selective #ITK inhibitor #soquelitinib reduces #TCR signal strength, moderates #mTOR activity.
These cell signal adjustments select for #Th1 and memory CD8+ cells to fight cancer and #Treg to rebalance immune system, while blocking #Th2 and #Th17 that cause autoimmune diseases across spectrum from #AtD #asthma #COPD to #psoriasis #IBD etc
Tzield slows the onset of type 1 diabetes, potentially for years. Here is Richard's story. https://t.co/qvngic7ppK #type1diabetes #cure #tzield #t1d @SanofiUS
We're doing stuff over here: https://t.co/YfSqSSchVK #teplizumab #Tzield #T1D #prevention @Norton_Health @NortonProvider @NortonChildrens @NCProvider @UofLPeds
Annual blog posting of all clinical trials aimed at curing, preventing, or delaying type-1 diabetes. Describes which funded by #JDRF and which not. Great overview of all clinical trials.
https://t.co/Sv6pt4PLMp
#T1D #type1diabetes
Big new news this year was #teplizumab/#Tzield
An exciting new study supported by #JDRFCanada & #CIHR provides clues about #T1D risk and progression – plus factors that could predict who will benefit most from #Tzield treatment.
New #SKResearch by Dr. Jayne Danska in @ScienceTM identifies antibody responses against normal gut bacteria that assist in identification of children at risk for type one diabetes. #T1D
Read ➡️ https://t.co/bK6Q23idOg
Teplizumab #Tzield included in @TIME magazine's Best Inventions of 2023. Way to go @kickassscience1!
https://t.co/yU2Ppx3ndo
TIME's new cover: Introducing the Best Inventions of 2023 https://t.co/0Qqre15KEN
#Tzield (teplizumab) now proven to protect insulin production in kids with #type1diabetes! Learn how this FDA-approved treatment helps, even for those already on daily insulin. Screening is key for early detection! Explore at https://t.co/Zcb2rPbdDV
A new drug is providing hope to children and adults who are at risk for #type1diabetes. The drug is called #Tzield, and early studies show it delays the onset of the disease for 2 to 8 years in adults and children. Hear from Dr. Bryce Nelson on @myVPM https://t.co/m9fKDcqzdy
Last Seen Hashtags on Sotwe
nolimit
Seen from United Kingdom
รับงานแม่ริม
Seen from Thailand
incesto madre
Nolimits nolimits
Seen from Canada
tio
Seen from United States
CopyWagon
Seen from Indonesia
TEENAGE #TEENAGEGIRLS
Seen from Vietnam
kikikumings
Seen from United States
棉花糖女孩
Seen from United States
alanyatraveſti
Seen from Turkey
Most Popular Users
Elon Musk 
@elonmusk
240.6M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.6M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.6M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.7M followers
Taylor Swift
@taylorswift13
81.5M followers
Lady Gaga
@ladygaga
73M followers
Virat Kohli
@imvkohli
69.9M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.9M followers
Neymar Jr
@neymarjr
62.6M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.7M followers